Annals of Oncology Advance Access originally published online on November 1, 2006
Annals of Oncology 2007 18(2):317-323; doi:10.1093/annonc/mdl377
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
lung cancer |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
1 Department of Internal Medicine, National Cancer Center Hospital, Tokyo
2 Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, The University of Tokyo, Tokyo
3 Thoracic Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba
4 Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Osaka
5 Department of Thoracic Oncology, Hyogo Medical Center for Adults, Akashi, Hyogo
6 Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
* Correspondence to: Dr Y. Ohe, Department of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel: +81-3-3542-2511; Fax: x+81-3-3542-7006; E-mail: yohe{at}ncc.go.jp
Background: To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design.
Patients and methods: A total of 602 patients were randomly assigned to one of four regimens: cisplatin 80 mg/m2 on day 1 plus irinotecan 60 mg/m2 on days 1, 8, 15 every 4 weeks (IP) carboplatin AUC 6.0 min x mg/mL (area under the concentration–time curve) on day 1 plus paclitaxel 200 mg/m2 on day 1 every 3 weeks (TC); cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1, 8 every 3 weeks (GP); and cisplatin 80 mg/m2 on day 1 plus vinorelbine 25 mg/m2 on days 1, 8 every 3 weeks (NP).
Results: The response rate, median survival time, and 1-year survival rate were 31.0%, 13.9 months, 59.2%, respectively, in IP; 32.4%, 12.3 months, 51.0% in TC; 30.1%, 14.0 months, 59.6% in GP; and 33.1%, 11.4 months, 48.3% in NP. No statistically significant differences were found in response rate or overall survival, but the non-inferiority of none of the experimental regimens could be confirmed. All the four regimens were well tolerated.
Conclusion: The four regimens have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.
Key words: carboplatin, cisplatin, gemcitabine, irinotecan, non-small-cell lung cancer, paclitaxel, randomized phase III study, vinorelbine
Received for publication May 16, 2006. Revision received August 13, 2006. Accepted for publication August 30, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Takeda, T. Hida, T. Sato, M. Ando, T. Seto, M. Satouchi, Y. Ichinose, N. Katakami, N. Yamamoto, S. Kudoh, et al. Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203) J. Clin. Oncol., February 10, 2010; 28(5): 753 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mitsudomi Advances in Target Therapy for Lung Cancer Jpn. J. Clin. Oncol., February 1, 2010; 40(2): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Neubauer, J. R. Hoverman, M. Kolodziej, L. Reisman, S. K. Gruschkus, S. Hoang, A. A. Alva, M. McArthur, M. Forsyth, T. Rothermel, et al. Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non-Small-Cell Lung Cancer in the Community Setting J. Oncol. Pract, January 1, 2010; 6(1): 12 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamada, K. Matsumoto, W. Wang, Q. Li, Y. Nishioka, Y. Sekido, S. Sone, and S. Yano Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer Clin. Cancer Res., January 1, 2010; 16(1): 174 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Azzoli, S. Baker Jr, S. Temin, W. Pao, T. Aliff, J. Brahmer, D. H. Johnson, J. L. Laskin, G. Masters, D. Milton, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2009; 27(36): 6251 - 6266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fujii, H. Kunikane, H. Okamoto, K. Watanabe, H. Kunitoh, K. Mori, A. Yokoyama, H. Fukuda, T. Tamura, and N. Saijo A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510 Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 784 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hiramatsu, Y. Iwasaki, Y. Koyama, N. Tamiya, S. Hosogi, M. Nakanishi, Y. Kohno, M. Ueda, T. Arimoto, and Y. Marunaka Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 779 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Clin. Cancer Res., November 1, 2009; 15(21): 6630 - 6638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer Ann. Onc., October 8, 2009; (2009) mdp401v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. West, D. Harpole, and W. Travis Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer Chest, October 1, 2009; 136(4): 1112 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. W. MOON, J. H. SOHN, Y. T. KIM, H. CHANG, J. H. JEONG, Y. J. LEE, J. CHANG, S. K. KIM, M. JUNG, S. HONG, et al. Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer Anticancer Res, October 1, 2009; 29(10): 4243 - 4249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, and K. Watanabe Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 569 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gandara, T. Kawaguchi, J. Crowley, J. Moon, K. Furuse, M. Kawahara, S. Teramukai, Y. Ohe, K. Kubota, S. K. Williamson, et al. Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics J. Clin. Oncol., July 20, 2009; 27(21): 3540 - 3546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J.-i. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment Clin. Cancer Res., July 1, 2009; 15(13): 4348 - 4355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, et al. Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer Anticancer Res, May 1, 2009; 29(5): 1733 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach Oncologist, May 1, 2009; 14(5): 497 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shukuya, T. Takahashi, A. Tamiya, A. Ono, S. Igawa, A. Tsuya, Y. Nakamura, H. Murakami, T. Naito, K. Kaira, et al. Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 158 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, et al. Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations Cancer Res., November 15, 2008; 68(22): 9479 - 9487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al. Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al. Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O'Byrne, T. Welte, R. Kolb, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann. Onc., February 1, 2008; 19(2): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr Editor-in- New wave Ann. Onc., January 1, 2008; 19(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
S. Ramalingam and C. Belani Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Oncologist, January 1, 2008; 13(suppl_1): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takatani, H. Soda, Y. Nakamura, A. Kinoshita, M. Fukuda, S. Nagashima, M. Fukuda, Y. Soejima, H. Nakano, M. Oka, et al. Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., May 1, 2007; 37(5): 353 - 357. [Abstract] [Full Text] [PDF]
|
|